Javascript must be enabled to continue!
GW24-e3511 Efficacy and prognosis of low molecular weight heparin (LMWH) in the treatment for the patients with chronic cor pulmonale during acute attack
View through CrossRef
Objectives
To investigate the efficacy and prognosis of low molecular weight heparin (LMWH) in the treatment for the patients with chronic cor pulmonale during acute attack.
Methods
320 cases patients with chronic cor pulmonale during acute attack, were at random divided into study group (167 cases) and control group (153 cases) all the patients in two groups were given the same routine treatments such as anti-infection, expectorant, relieving spasm, balancing hydro-electrolytic disorder, low flow oxygen inhalation, and conventional digitals, diuretics, vasodilators therapy. In study group, besides routine treatment, low molecular weight heparin (LMWH) was given. compared clinical features, laboratory results in the two groups before and after the treatment. We followed up these cases during 90 days after treatment, the patients in both groups were observed for comparison of the clinical effect, major adverse events rate, complication, stroke and the death of 90 days.
Results
Clinical features, laboratory results in study group were markedly improved after the treatment than those in control group (91% VS 82%) (P < 0.05), the patient in control group was associated with an increase numbers of hospitalisation and shorter time interval for readmission for the patients with chronic cor pulmonale during acute attack (P < 0.05). Morbidity from brain stroke is more frequent in control group than those in study group, 11/167 VS 3/153 (P < 0.05).
Conclusions
Low molecular weight heparin (LMWH) was effective to the patients with chronic cor pulmonale during acute attack.
Title: GW24-e3511 Efficacy and prognosis of low molecular weight heparin (LMWH) in the treatment for the patients with chronic cor pulmonale during acute attack
Description:
Objectives
To investigate the efficacy and prognosis of low molecular weight heparin (LMWH) in the treatment for the patients with chronic cor pulmonale during acute attack.
Methods
320 cases patients with chronic cor pulmonale during acute attack, were at random divided into study group (167 cases) and control group (153 cases) all the patients in two groups were given the same routine treatments such as anti-infection, expectorant, relieving spasm, balancing hydro-electrolytic disorder, low flow oxygen inhalation, and conventional digitals, diuretics, vasodilators therapy.
In study group, besides routine treatment, low molecular weight heparin (LMWH) was given.
compared clinical features, laboratory results in the two groups before and after the treatment.
We followed up these cases during 90 days after treatment, the patients in both groups were observed for comparison of the clinical effect, major adverse events rate, complication, stroke and the death of 90 days.
Results
Clinical features, laboratory results in study group were markedly improved after the treatment than those in control group (91% VS 82%) (P < 0.
05), the patient in control group was associated with an increase numbers of hospitalisation and shorter time interval for readmission for the patients with chronic cor pulmonale during acute attack (P < 0.
05).
Morbidity from brain stroke is more frequent in control group than those in study group, 11/167 VS 3/153 (P < 0.
05).
Conclusions
Low molecular weight heparin (LMWH) was effective to the patients with chronic cor pulmonale during acute attack.
Related Results
Impact of Common Anticoagulants on Complete Blood Count Parameters Among Humans
Impact of Common Anticoagulants on Complete Blood Count Parameters Among Humans
Abstract
Introduction
Among the most frequently used anticoagulants in hematological testing are tetra-acetic acid (EDTA), sodium citrate, and sodium heparin. However, there is a n...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Comparing the safety of direct oral anticoagulants vs. low-molecular-weight heparin in patients with thrombocytopenia and venous thromboembolism
Comparing the safety of direct oral anticoagulants vs. low-molecular-weight heparin in patients with thrombocytopenia and venous thromboembolism
Abstract
Introduction: Balancing the safety and efficacy of anticoagulation (AC) for venous thromboembolism (VTE) among ...
Novel ELISA-Based Assay for Detection of Complement Activation By PF4/Heparin Complexes
Novel ELISA-Based Assay for Detection of Complement Activation By PF4/Heparin Complexes
Abstract
The immune response to platelet factor 4 (PF4)/heparin complexes is a frequent iatrogenic complication of heparin therapy associated with development of hep...
Clinical Outcomes with Unfractionated Heparin or Low-Molecular-Weight Heparin as Bridging Therapy in Patients on Long-Term Oral Anticoagulants: Results from the REGIMEN Registry.
Clinical Outcomes with Unfractionated Heparin or Low-Molecular-Weight Heparin as Bridging Therapy in Patients on Long-Term Oral Anticoagulants: Results from the REGIMEN Registry.
Abstract
Introduction: The optimal perioperative management of patients on long-term oral anticoagulant (OAC) therapy is currently unclear. There have been no large ...
HEPARIN BINDING TO HUMAN MONOCYTES: MODULATION BY HISTIDINE-RICH GLYCOPROTEIN
HEPARIN BINDING TO HUMAN MONOCYTES: MODULATION BY HISTIDINE-RICH GLYCOPROTEIN
Heparin and its related glycosaminoglycans interact with a variety of cell types and, irrespective of their anticoagulant activities, have a complex and biologically important infl...
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...

